Oramed Pharmaceuticals
Pharmaceutical company based in Israel
ORMP Tel Aviv Stock Exchange · home listing
Tel Aviv Stock Exchange
Nasdaq
ORMP Nasdaq
ISIN US68403P2039 SEC CIK 1176309 LEI 5299006K52ZIIGQJ6R84
Follow Oramed Pharmaceuticals
Weekly email: filings, results
Net income
$18.4M
−62% vs same quarter last year
EPS, diluted
$0.43
−61.9% vs same quarter last year
Operating cash flow
$426K
+126.2% vs same quarter last year
Operating income
−$4.1M
−69.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $2M | $75.3K |
| FY24 | - | −$15.9K |
| FY23 | $1.3M | $5.1K |
| FY22 | $2.7M | −$36.6M |
| FY21 | $2.7M | - |
| FY20 | $2.7M | - |
| FY19 | $2.7M | - |
| FY18 | $2.4M | - |
| FY17 | $2.5M | - |
| FY16 | $641K | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | $4.2M |
| FY12 | - | - |
| FY11 | - | −$1.6M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 0.6% | −754.4% | 3.8% |
| FY24 | - | - | - |
| FY23 | - | −1176.8% | 0.4% |
| FY22 | - | −1502% | −1352.6% |
| FY21 | - | −896.2% | - |
| FY20 | - | −433.8% | - |
| FY19 | 96.7% | −541.3% | - |
| FY18 | - | −552.3% | - |
| FY17 | 92.4% | −438.6% | - |
| FY16 | 23.6% | −1561.6% | - |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$9.2M |
| FY24 | −$8.4M |
| FY23 | −$10.5M |
| FY22 | −$28.4M |
| FY21 | −$21.6M |
| FY20 | −$12.5M |
| FY19 | −$13M |
| FY18 | −$14.7M |
| FY17 | −$5.8M |
| FY16 | $4.6M |
| FY15 | −$4.9M |
| FY14 | −$4.1M |
| FY13 | −$3.4M |
| FY12 | −$2.3M |
| FY11 | −$1.7M |
- Oramed Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Oramed Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 3.8% | −30.6% |
| FY24 | - | −47% |
| FY23 | 0.4% | −58% |
| FY22 | −1352.6% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |